iNANOD AS

iNANOD AS, an ambitious micro-pharma company revolutionising cancer treatment through targeted and faster drug delivery to solid malignant tumours. iNANOD utilizes nanotechnology to improve drug delivery within cancer chemotherapy, allowing for the targeted and accelerated delivery of active pharmaceutical ingredients. iNANOD founders envisioned a future where nanotechnology, in combination with biotechnology, could transform cancer treatment. iNANOD AS operates on a lean model, strongly supported by a group of experienced advisors, and is dedicated to improving the precision and efficiency of drug delivery to solid tumours. By leveraging market-pull mechanisms of innovation, the company aims to address one of the most pressing challenges in oncology: ensuring that a higher percentage of injected doses reach tumour sites, thereby enhancing treatment efficacy while minimising side effects.